TFA’s China Licensee HuanZhang Enters Shanghai Pharma’s Supply Chain

TFA Therapeutics, Inc. (OTCQB: RAJAF) announced that HuanZhang, its exclusive development and commercialization partner in China, has entered the Shanghai Pharmaceuticals group’s supply chain for Antrodia camphorata raw material. The customer is Chongqing Shangyao Huiyuan Qinglong Pharmaceutical Co., Ltd. (Chongqing SPH). Shanghai Pharmaceuticals is a large pharmaceutical group listed in both Shanghai and Hong Kong and ranked No. 411 on the 2026 Fortune Global 500.

This also marks Chongqing SPH’s first Antrodia camphorata raw-material program. Based on records for the supply engagement, HuanZhang was the program’s only qualified supplier as of September 18, 2026. In commercial terms, the qualification indicates that a supplier has cleared a major customer’s internal quality and delivery requirements and moved from a prospective source into an active supply chain.

Chongqing SPH commissioned the Testing Center of the Guangdong Institute of Traditional Chinese Medicine to test the sample with reference to the Guangdong quality standard for Antrodia camphorata as a Chinese medicinal material (Report No. 2026090272D001). DNA barcoding showed a 99.82% match with Taiwanofungus camphoratus.

According to raw-material specifications supplied by HuanZhang, the batch contained at least 1,500 ppm of Antcin A. This figure is HuanZhang-provided compositional information and was not part of the testing commissioned by Chongqing SPH.

For TFA, this supply engagement demonstrates its China licensee’s practical capabilities in material identification, quality documentation, batch traceability, and delivery that meets applicable requirements. These capabilities support drug development, manufacturing, and market entry in China. Qualification to supply a Chinese medicinal material does not validate a new veterinary drug.

TFA has licensed HuanZhang to undertake the development, regulatory filing, and commercialization of TFA-01 in mainland China. TFA-01 is an Antcin A-based drug candidate with canine osteoarthritis as its initial target indication, and formulation, safety, and efficacy work remains in progress. The quality requirements for supplying Antrodia camphorata as a medicinal material are not the same as those for the TFA-01 drug substance or a new veterinary drug submission; however, the supply-chain experience gained through this engagement will support HuanZhang’s preparations for local operations in China.

This raw-material supply engagement does not indicate Shanghai Pharma’s participation in TFA-01 development or certification of the stated Antcin A content. It also does not mean that TFA-01 has passed China’s new veterinary drug review, received marketing authorization, or been approved for sale.